[A16-70] Benefit assessment of biotechnologically produced drugs for the treatment of rheumatoid arthritis

Last updated 17.09.2019

Project no.:
A16-70

Commission:
Commission awarded on 24.11.2016 by the Federal Joint Committee (G-BA).

Report type:
Report

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Muscles, bones and joints

17.09.2019

Biologics in rheumatoid arthritis: better evidence, but direct comparisons still lacking

Only few differences between biologics detectable / Operationalization of outcomes can influence results

Current document

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.